@entity1261 priming, @entity19859 , and high dose XXXX (GCLAC) for upfront treatment of @entity3052 , advanced @entity2590 or @entity1442 .

@entity1 @entity137 @entity1261 @entity5 @entity2590 @entity3052 @entity2592 @entity3118 @entity1442 @entity1503 @entity9713 @entity19859 @entity4434
Prior study of the combination of @entity19859 and high dose @entity2592 with @entity1261 ( @entity1261 ) priming (GCLAC) in relapsed or refractory @entity3052 resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG ( @entity3118 , @entity2592 , @entity1261 ) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and @entity4434 ), and @entity137 of GCLAC. @entity19859 was administered at 30 mg m(-2) day(-1) * 5 and @entity2592 at 2 g m(-2) day(-1) * 5 after @entity1261 priming in 50 newly-diagnosed @entity1 ages 18-64 with @entity3052 or advanced @entity2590 ( @entity2590 ) or @entity1442 ( @entity5 ). Responses were assessed in the different cytogenetic risk groups and in @entity1 with @entity1503 . The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for @entity1 with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For @entity1 with an @entity1503 ( @entity1503 ), the CR rate was 65%, compared to 85% for those without an @entity1503 . The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for @entity3052 and advanced @entity9713 .
